Cross Country Healthcare (CCRN)
(Delayed Data from NSDQ)
$12.33 USD
+0.15 (1.23%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $12.33 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.33 USD
+0.15 (1.23%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $12.33 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth A Momentum A VGM
Zacks News
Cross Country Healthcare (CCRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cross Country Healthcare (CCRN) closed at $20.83, marking a +0.39% move from the previous day.
Why a Hold Strategy is Apt for ABM Industries (ABM) Stock Now
by Zacks Equity Research
ELEVATE is expected to significantly accelerate ABM Industries' (ABM) organic growth, improve its strategic and comprehensive positioning, and reinforce profitability.
FactSet (FDS) Rides on Robust Top Line, Low Liquidity Ails
by Zacks Equity Research
The recent buyout of CUSIP Global Services from S&P Global is expected to significantly boost FactSet's (FDS) open data strategy and expand its position in the global capital markets.
Reasons Why a Hold Strategy is Apt for Rollins (ROL) Stock Now
by Zacks Equity Research
Rollins (ROL) has a track record of consistent dividend payments.
Here's Why You Should Retain Booz Allen (BAH) Stock for Now
by Zacks Equity Research
Vision 2020 and a large addressable market boost Booz Allen (BAH). A weak capital position is, however, worrisome.
Accenture (ACN) to Gain From XtremeEDA Buyout: Here's How
by Zacks Equity Research
The deal is likely to help Accenture (ACN) expand its silicon design capabilities in Canada and the United States.
Boxlight (BOXL) Launches New AV Campus Communication Solution
by Zacks Equity Research
The move is a part of Boxlight's (BOXL) campus communication strategy.
Accenture (ACN), Johnson Controls to Operate Innovation Centers
by Zacks Equity Research
Accenture (ACN) will provide technologies like digital twins, 5G and Internet of Things, AI-driven analytics, and environmental information to Johnson Controls.
Boxlight (BOXL) Launches New Redesigned User-Friendly Website
by Zacks Equity Research
The move is a part of Boxlight's (BOXL) continuous drive toward becoming a leading provider of interactive technology solutions and services globally.
Why a Hold Strategy is Apt for IQVIA Holdings (IQV) Stock Now
by Zacks Equity Research
IQVIA's (IQV) enormous treasure trove of information is a distinguishing asset.
Here's Why You Should Hold on to Accenture (ACN) Stock For Now
by Zacks Equity Research
Accenture (ACN) has been steadily gaining traction in its consulting as well as outsourcing businesses.
Republic Services (RSG) Stock Up 16.4% in a Year: Here's Why
by Zacks Equity Research
Consecutive better-than-expected top and bottom-line performances, and shareholder-friendly moves have been aiding Republic Services??? (RSG) stock.
Reasons to Retain TransUnion (TRU) Stock in Your Portfolio
by Zacks Equity Research
TransUnion's (TRU) addressable market includes the burgeoning Big Data and analytics market.
Cross Country Healthcare (CCRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cross Country Healthcare (CCRN) closed at $18.83, marking a +1.02% move from the previous day.
Omnicom (OMC) Announces Strategic Partnership With Instacart
by Zacks Equity Research
Through the collaboration, Omnicom (OMC) and Instacart can help brands understand which products suit their audiences through basket analysis and assessment of content consumption trends.
Automatic Data Processing (ADP) Up 6% in a Year: Here's Why
by Zacks Equity Research
The Automatic Data Processing (ADP) stock has been benefiting from consecutive better-than-expected top and bottom-line performances and encouraging guidance.
Wall Street Analysts Predict a 93% Upside in Cross Country (CCRN): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 93.1% in Cross Country (CCRN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Investors Should Buy FTI Consulting (FCN) Stock Now
by Zacks Equity Research
Investor-friendly steps and a strong balance sheet are aiding FTI Consulting (FCN) stock.
Cross Country (CCRN) Stock Jumps 7.1%: Will It Continue to Soar?
by Zacks Equity Research
Cross Country (CCRN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
6 Reasons You Should Invest in Avis Budget (CAR) Stock Now
by Zacks Equity Research
Avis Budget (CAR) continues to benefit from acquisitions, technology enhancement and fleet expansion.
Reasons Why Investors Should Retain Verisk (VRSK) Stock For Now
by Zacks Equity Research
Verisk's (VRSK) growth strategy focuses on organic growth, product development and acquisitions.
DocuSign (DOCU) Gains From eSignature Strength Amid Expense Woes
by Zacks Equity Research
DocuSign (DOCU) remains focused on continuously acquiring eSignature customers, expanding eSignature use cases within existing customers and improving its offerings.
Reasons to Retain Trane Technologies' (TT) Stock For Now
by Zacks Equity Research
Trane Technologies (TT) has a consistent record of rewarding its shareholders through dividend payments and share repurchases.
Here's Why You Should Hold WEX Stock in Your Portfolio For Now
by Zacks Equity Research
Acquisitions are contributing significantly to WEX's revenue growth and enhancing the latter's scalability.
The Zacks Analyst Blog Highlights Avnet, Cross Country Healthcare, Hudson Global and Tenaris
by Zacks Equity Research
Avnet, Cross Country Healthcare, Hudson Global and Tenaris have been included in this Analyst Blog.